Rchr

J-GLOBAL ID：201901020407683052 Update date: Dec. 19, 2022

Katsuya Nakai

ナカイカツヤ | Katsuya Nakai

Affiliation and department：

Research keywords (2)： Triple Negative Breast Cancer , 乳癌

Papers (24)：

Lee Pei-Chih, Fang Yueh-Fu, Yamaguchi Hirohito, Wang Wei-Jan, Chen Tse-Ching, Hong Xuan, Ke Baozhen, Xia Weiya, Wei Yongkun, Zha Zhengyu, et al. Targeting PKC delta as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. CANCER CELL. 2018. 34. 6. 954-+
Horimoto Yoshiya, Tokuda Emi, Murakami Fumi, Uomori Toshitaka, Himuro Takanori, Nakai Katsuya, Orihata Gotaro, Iijima Kotaro, Togo Shinsaku, Shimizu Hideo, et al. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. JOURNAL OF TRANSLATIONAL MEDICINE. 2018. 16
Yamaguchi H, Du Y, Nakai K, Ding M, Chang S-S, Hsu J. L, Yao J, Wei Y, Nie L, Jiao S, et al. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. ONCOGENE. 2018. 37. 2. 208-217
Katsuya Nakai, Weiya Xia, Hsin-Wei Liao, Mitsue Saito, Mien-Chie Hung, Hirohito Yamaguchi. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer. 2018. 25. 1. 74-80
中井克也, 齊藤光江. 【知っておきたい乳がん診療のエッセンス】治療編内科的治療内分泌療法・分子標的療法(術前・術後・再発). 臨床外科. 2017. 72. 9. 1074-1078

ｍore...

MISC (196)：

ｍore...

Association Membership(s) (3)：

JAPAN SURGICAL SOCIETY , 日本乳癌学会 , JAPAN SOCIETY OF CLINICAL ONCOLOGY

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM